Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Spherusol Generic Name & Formulations
Legal Class
Rx
General Description
Coccidioides immitis spherule-derived skin test antigen 1.27mcg/0.1mL; soln for intradermal inj; contains phenol.
Pharmacological Class
Antigen test.
How Supplied
Multi-dose vial (1mL)—1
Manufacturer
Generic Availability
NO
Spherusol Indications
Indications
To detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.
Limitations of Use
Use in patients with unknown exposure to C. immitis is not evaluated. Patients with acute or disseminate coccidioidomycosis, immunodeficiency and history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol.
Spherusol Dosage and Administration
Adult
Give by intradermal inj. 18–64yrs: 0.1mL to the volar surface of forearm. Assess for induration at 48±4hrs after administration. Mean induration ≥5mm: positive for delayed-type hypersensitivity response.
Children
<18yrs: not established.
Spherusol Contraindications
Not Applicable
Spherusol Boxed Warnings
Boxed Warning
Larger accelerated reactions may occur. Systemic reactions; may be life-threatening or fatal. Not for IV inj.
Spherusol Warnings/Precautions
Warnings/Precautions
Review medical history for skin test sensitivity and related adverse reactions. Have trained personnel and medical equipment readily available. Monitor for ≥30mins post inj for adverse reactions. Immunosuppression. Infection. Elderly. Pregnancy (Cat.C). Nursing mothers.
Spherusol Pharmacokinetics
See Literature
Spherusol Interactions
Interactions
Concomitant beta-blockers may antagonize epinephrine inj. Concomitant corticosteroids and immunosuppressants may suppress response to the skin test.
Spherusol Adverse Reactions
Adverse Reactions
Itching, swelling, pain; anaphylactic reactions.
Spherusol Clinical Trials
See Literature
Spherusol Note
Not Applicable
Spherusol Patient Counseling
See Literature
